It’s been a heck of a week (and it’s only Tuesday).
Today on Post-Hoc Live at 11 a.m. ET, I’ll be joined by my colleague at the Financial Times, Global Pharmaceutical Editor Hannah Kuchler. Next week, we’ll both be in London for the FT and Endpoints News Global Pharma and Biotech Summit, and we wanted to give you a preview of what we’ll be talking about, and also how we’re thinking about some of the very busy, very chaotic stories we’re both covering right now.
You can join us on YouTube, or set a calendar reminder for when we go live in a few hours.
Hannah and I are going to hit the latest on the M&A drama between Pfizer, Metsera and Novo Nordisk just as Pfizer’s earnings call is wrapping up. We’ll talk about the new Novo and its aggressive CEO. We’ll get into all things Washington, D.C., from the turmoil at the FDA to how we think the next round of MFN announcements will go. And Hannah will give her view from the UK on how our friends in Europe look at what’s happening here in the US.
If you’re in London, or you’d like to join us virtually next week, you can check out the agenda for the Global Pharma and Biotech Summit. (You can use the code POSTHOC20 to save on your virtual registration.)
See you in a few hours!
— Drew